Literature DB >> 19036117

Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis.

Mark A Scheper1, Ashraf Badros, Risa Chaisuparat, Kevin J Cullen, Timothy F Meiller.   

Abstract

Osteonecrosis of the jaw secondary to bisphosphonate infusion (zoledronic acid-ZA) is assumed to be a bone disease. This study investigated the effects of ZA on soft tissues using oral mucosal cells as an in vitro model of soft tissue cell death in the pathogenesis of bone necrosis. Human gingival fibroblast and keratinocyte cell lines were exposed to different concentrations of ZA (0.25-3 micromol/l), using 1 micromol/l as the expected baseline concentration. A dose-response effect on apoptosis and cell proliferation [Terminal deoxynucleotidyl transferase-mediated dUTP-Biotin End Labelling and Annexin V or Coulter counter and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), respectively] was observed with increasing ZA concentrations; both reversed using siRNA against caspase 3 or 9. Gene expression analysis using RT(2) Profiler polymerase chain reaction Arrays demonstrated the differential expression of multiple genes involved in apoptosis including those that encode TNF, BCL-2, Caspase, IAP, TRAF and Death Domain families. Western blot analysis confirmed the presence of activated forms of caspase 3 and 9 and underexpression of survivin protein expression. This study demonstrated that low concentrations of ZA rapidly and directly affected the oral mucosal tissues though the induction of a gene-regulated apoptotic process. These findings support the potential for soft tissue injury as an initiating/potentiating event for osteonecrosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036117      PMCID: PMC2739302          DOI: 10.1111/j.1365-2141.2008.07504.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  30 in total

1.  Antitumor activity of bisphosphonates.

Authors:  Matthew R Smith
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

Review 2.  Bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Eur Spine J       Date:  2003-09-16       Impact factor: 3.134

Review 3.  Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention.

Authors:  Frank L Lanza
Journal:  Treat Endocrinol       Date:  2002

Review 4.  Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.

Authors:  Jose V Bagan; Yolanda Jimenez; Judith Murillo; Sergio Hernandez; Rafael Poveda; José M Sanchis; José M Diaz; Crispian Scully
Journal:  Oral Oncol       Date:  2005-11-04       Impact factor: 5.337

Review 5.  Bone resorption and turnover in health and disease.

Authors:  G R Mundy
Journal:  Bone       Date:  1987       Impact factor: 4.398

6.  Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Authors:  Tony Mavrokokki; Andrew Cheng; Brien Stein; Alastair Goss
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

7.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

Review 8.  Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis.

Authors:  Marjorie Jeffcoat; Nelson B Watts
Journal:  Gen Dent       Date:  2008 Jan-Feb

Review 9.  Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.

Authors:  Serge C L M Cremers; Goonaseelan Pillai; Socrates E Papapoulos
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

10.  Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.

Authors:  M Goffinet; M Thoulouzan; A Pradines; I Lajoie-Mazenc; Carolyn Weinbaum; J C Faye; S Séronie-Vivien
Journal:  BMC Cancer       Date:  2006-03-15       Impact factor: 4.430

View more
  43 in total

Review 1.  Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.

Authors:  Cesar A Migliorati; Joel B Epstein; Elliot Abt; James R Berenson
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

2.  Bisphosphonates induce senescence in normal human oral keratinocytes.

Authors:  R H Kim; R S Lee; D Williams; S Bae; J Woo; M Lieberman; J-E Oh; Q Dong; K-H Shin; M K Kang; N-H Park
Journal:  J Dent Res       Date:  2011-03-22       Impact factor: 6.116

Review 3.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

4.  Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap.

Authors:  Juliana Lemound; Andrè Eckardt; Horst Kokemüller; Constantin von See; Pit Jacob Voss; Frank Tavassol; Martin Rücker; Majeed Rana; Nils-Claudius Gellrich
Journal:  Clin Oral Investig       Date:  2011-08-05       Impact factor: 3.573

Review 5.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

6.  Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.

Authors:  Matthew Cozin; Bradley M Pinker; Kimberley Solemani; Jeremy M Zuniga; Stephen C Dadaian; Serge Cremers; Regina Landesberg; Srikala Raghavan
Journal:  J Oral Maxillofac Surg       Date:  2011-07-31       Impact factor: 1.895

7.  The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

Authors:  Andreas M Pabst; Thomas Ziebart; Felix P Koch; Katherine Y Taylor; Bilal Al-Nawas; Christian Walter
Journal:  Clin Oral Investig       Date:  2011-01-12       Impact factor: 3.573

8.  IL-4 administration exerts preventive effects via suppression of underlying inflammation and TNF-α-induced apoptosis in steroid-induced osteonecrosis.

Authors:  X Wu; X Feng; Y He; Y Gao; S Yang; Z Shao; C Yang; H Wang; Z Ye
Journal:  Osteoporos Int       Date:  2016-01-11       Impact factor: 4.507

9.  Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.

Authors:  J Ignacio Aguirre; Mohammed P Akhter; Donald B Kimmel; Jennifer E Pingel; Alyssa Williams; Marda Jorgensen; Lakshmyya Kesavalu; Thomas J Wronski
Journal:  J Bone Miner Res       Date:  2012-10       Impact factor: 6.741

10.  A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis.

Authors:  Ma Scheper; R Chaisuparat; Kj Cullen; Tf Meiller
Journal:  Fibrogenesis Tissue Repair       Date:  2010-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.